HIVEP3 and osteoporosis: Mice lacking critical residues in the MAPK-binding motif of SHN3 or mice treated to reduce the expression of endogenous SHN3 nevertheless displayed few phenotypic changes beyond increased adult bone mass, identifying SHN3 as an attractive drug target for osteoporosis and fracture-repair treatments (Yang et al., 2019 ▸).